Trials / Unknown
UnknownNCT02256514
Open Label Trial of Immunotherapy for Advanced Liver Cancer
Open Label Trial of Hepcortespenlisimut-L (V5) Immunotherapy for HCC
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Immunitor LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate daily dosing of oral immunotherapy hepcortespenlisimut-L (V5) in patients with advanced stage of HCC not amenable to surgical intervention or with recurrent tumor after surgery.
Detailed description
Hepcortespenlisimut-L (V5) immunotherapy of HCC in an open label setting with baseline alphafetoprotein serum levels and CT scan image as primary endpoints with monthly follow-up thereafter. Additional endpoints will include blood biochemistry indices and safety monitoring.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Daily oral dose of hepcortespenlisimut-L | Oral therapeutic vaccine, hepcortespenlisimut-L (V5) to be given once-per-day with monthly check-up |
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2019-09-01
- Completion
- 2019-12-01
- First posted
- 2014-10-03
- Last updated
- 2019-08-30
Locations
1 site across 1 country: Mongolia
Source: ClinicalTrials.gov record NCT02256514. Inclusion in this directory is not an endorsement.